欢迎访问心血管病防治知识,今天是

心血管病防治知识 ›› 2024, Vol. 14 ›› Issue (22): 27-30.

• 临床研究 • 上一篇    下一篇

产前彩色多普勒超声检测DV参数与唐氏筛查联合诊断胎儿先天性心脏病效果观察

林晓艺   

  1. 漳州正兴医院, 福建 漳州 363000
  • 出版日期:2024-11-30 发布日期:2025-03-17

Value of ductus venosus parameters measured by antenatal color Doppler ultrasound combined with Down’s syndrome screening in the diagnosis of fetal congenital heart disease

LIN Xiaoyi   

  1. Zhangzhou Zhengxing Hospital, Zhangzhou 363000, China
  • Online:2024-11-30 Published:2025-03-17

摘要: 目的 探讨产前彩色多普勒超声检测静脉导管(DV)参数与唐氏筛查联合诊断胎儿先天性心脏病(CHD)的价值。方法 选取2020年1月至2024年5月本院行CHD筛查的1689名孕妇作为研究对象,均开展DV参数及唐氏筛查,并以妊娠终止后检查结果为金标准,统计胎儿CHD检出情况及诊断效能;并比较CHD胎儿与非CHD胎儿DV参数及甲胎蛋白(AFP)、游离雌三醇(uE3)、游离β-绒毛膜促性腺激素(β-hCG)差异。结果 1689名孕妇筛查经金标准共有60例确诊胎儿CHD;其中DV参数检查检出55例,阳性率为91.67%;唐氏筛查检出52例,阳性率为86.67%;联合检查检出59例,阳性率为98.33%;联合检查诊断胎儿CHD的灵敏度、准确度、阴性预测值高于单一检查,有统计学差异(P<0.05);CHD胎儿S/D、PI、PVIV、PLI为(5.86±0.85)、(1.68±0.23)、(1.18±0.22)、(1.06±0.19),高于非CHD胎儿的(3.97±0.47)、(1.05±0.19)、(0.89±0.15)、(0.76±0.13),有统计学差异(P<0.05);CHD胎儿AFP、β-hCG水平为(55.65±5.28)ng/mL、(5.87±1.12)U/L,高于非CHD胎儿的(48.63±4.35)ng/mL、(4.23±0.58)U/L,uE3水平为(1.22±0.23)ng/mL,低于非CHD胎儿的(1.61±0.25)ng/mL,有统计学差异(P<0.05)。结论 产前检测DV参数联合唐氏筛查可提高胎儿CHD检出准确性,便于早期干预,保障优生优育。

关键词: 先天性心脏病, 彩色多普勒超声, 静脉导管, 唐氏筛查, 诊断价值

Abstract: Objective To investigate the value of ductus venosus (DV) parameters measured by antenatal color Doppler ultrasound combined with Down’s syndrome screening in the diagnosis of fetal congenital heart disease (CHD).Methods A total of 1689 pregnant women who underwent CHD screening in our hospital from January 2020 to May 2024 were enrolled as subjects. Measurement of DV parameters and Down’s syndrome screening were performed for all subjects, and the detection rate of fetal CHD and diagnostic efficacy were analyzed based on the gold standard of examination results after termination of pregnancy. The fetuses with CHD and those without CHD were compared in terms of DV parameters, alpha-fetoprotein (AFP), unconjugated estriol (uE3), and free β-human chorionic gonadotropin (β-hCG). Results Among the 1689 pregnant women, 60 were diagnosed with fetal CHD based on the gold standard, among whom 55 were detected by DV parameters, with a positive rate of 91.67%, and 52 were detected by Down’s syndrome screening, with a positive rate of 86.67%, while 59 were detected by the combination of DV parameters and Down’s syndrome screening, with a positive rate of 98.33%. The combination of DV parameters and Down’s syndrome screening had significantly higher sensitivity, accuracy, and negative predictive value than each examination alone (P <0.05). The fetuses with CHD had significantly higher values of S/D, PI, PVIV, and PLI than those without CHD (S/D: 5.86±0.85 vs 3.97±0.47, P <0.05; PI: 1.68±0.23 vs 1.05±0.19, P <0.05; PVIV: 1.18±0.22 vs 0.89±0.15, P <0.05; PLI: 1.06±0.19 vs 0.76±0.13, P <0.05). Compared with the fetuses without CHD, the fetuses with CHD had significantly higher levels of AFP (55.65±5.28 ng/mL vs 48.63±4.35 ng/mL, P <0.05) and β-hCG (5.87±1.12 U/L vs 4.23±0.58 U/L, P <0.05) and a significantly lower level of uE3 (1.22±0.23 ng/mL vs 1.61±0.25 ng/mL, P <0.05). Conclusion Antenatal measurement of DV parameters combined with Down’s syndrome screening can improve the accuracy of CHD detection in fetuses, which can help with early intervention and guarantee good prenatal and postnatal care.

Key words: Congenital heart disease, Color Doppler ultrasound, Ductus venosus, Down’s syndrome screening, Diagnostic value